TABLE 3.
Variable (antibiotic exposure) | Bivariate result for the following comparisona: |
|||||
---|---|---|---|---|---|---|
ESBL vs control |
Non-ESBL vs control |
|||||
OR | 95% CI | P | OR | 95% CI | P | |
Broad-spectrum cephalosporins | 1.89 | 0.94-3.78 | 0.07 | 0.51 | 0.29-0.87 | 0.02 |
Narrow-spectrum cephalosporins | 0.74 | 0.33-1.62 | 0.45 | 0.74 | 0.49-1.11 | 0.14 |
Penicillins | 4.29 | 2.23-8.26 | <0.01 | 1.24 | 0.80-1.91 | 0.33 |
β-Lactam-β-lactamase inhibitor combinations | 13.48 | 4.35-41.74 | <0.01 | 2.38 | 0.93-6.14 | 0.07 |
Piperacillin | 2.94 | 0.20-44.13 | 0.44 | 1.33 | 0.17-10.66 | 0.79 |
Fluoroquinolones | 2.52 | 1.37-4.64 | 0.01 | 0.37 | 0.25-0.56 | <0.01 |
Aminoglycosides | 5.34 | 2.16-13.18 | <0.01 | 1.44 | 0.76-2.72 | 0.26 |
Clindamycin | 2.30 | 0.75-7.03 | 0.15 | 1.64 | 0.73-3.69 | 0.23 |
Metronidazole | 2.83 | 1.53-5.22 | <0.01 | 0.80 | 0.53-1.20 | 0.28 |
Trimethoprim-sulfamethoxazole | 1.00 | 0.32-3.20 | 1.00 | 0.44 | 0.19-1.04 | 0.06 |
Carbapenems | 0.46 | 0.07-3.28 | 0.44 | 0.32 | 0.07-1.42 | 0.13 |
Boldface indicates statistical significance.